Loading...
Docoh

QuidelOrtho (QDEL)

Quidel Corporation is a leading manufacturer of diagnostic solutions at the point of care, delivering a continuum of rapid testing technologies that further improve the quality of health care throughout the globe. An innovator for over 40 years in the medical device industry, Quidel pioneered the first FDA-cleared point-of-care test for influenza in 1999 and was the first to market a rapid SARS-CoV-2 antigen test in the U.S. Under trusted brand names Sofia®, Solana®, Lyra®, Triage® and QuickVue®, Quidel's comprehensive product portfolio includes tests for a wide range of infectious diseases, cardiac and autoimmune biomarkers, as well as a host of products to detect COVID-19. With products made in America, Quidel's mission is to provide patients with immediate and frequent access to highly accurate, affordable testing for the good of families, communities and the world.

Company profile

Ticker
QDEL
Exchange
Website
CEO
Douglas Bryant
Employees
Incorporated
Location
Fiscal year end
SEC CIK
Subsidiaries
Diagnostic Hybrids, Inc. • Quidel Cardiovascular Inc. • Quidel Ireland Limited • Quidel China Ltd. ...
IRS number
942573850

QDEL stock data

Analyst ratings and price targets

Last 3 months

Calendar

4 May 22
12 Aug 22
31 Dec 22
Quarter (USD) Mar 22 Dec 21 Sep 21 Jun 21
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS
Annual (USD) Dec 21 Dec 20 Dec 19 Dec 18
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS
Date Owner Security Transaction Code Indirect 10b5-1 $Price #Shares $Value #Remaining
27 May 22 Bryant Douglas C Common Stock Sale back to company Dispose D No No 0 505,926 0 0
27 May 22 Bryant Douglas C RSU Common Stock Sale back to company Dispose D No No 0 794 0 0
27 May 22 Bryant Douglas C RSU Common Stock Sale back to company Dispose D No No 0 2,646 0 0
27 May 22 Bryant Douglas C RSU Common Stock Sale back to company Dispose D No No 0 24,187 0 0
27 May 22 Bryant Douglas C RSU Common Stock Sale back to company Dispose D No No 0 27,043 0 0
27 May 22 Bryant Douglas C RSU Common Stock Sale back to company Dispose D No No 0 3,347 0 0
27 May 22 Bryant Douglas C RSU Common Stock Sale back to company Dispose D No No 0 2,921 0 0
27 May 22 Bryant Douglas C RSU Common Stock Sale back to company Dispose D No No 0 7,590 0 0
27 May 22 Bryant Douglas C RSU Common Stock Sale back to company Dispose D No No 0 2,192 0 0
27 May 22 Bryant Douglas C RSU Common Stock Sale back to company Dispose D No No 0 7,309 0 0
61.1% owned by funds/institutions
13F holders Current Prev Q Change
Total holders 352 361 -2.5%
Opened positions 65 81 -19.8%
Closed positions 74 36 +105.6%
Increased positions 141 117 +20.5%
Reduced positions 96 108 -11.1%
13F shares Current Prev Q Change
Total value 4.57B 5.39B -15.2%
Total shares 40.89M 40.94M -0.1%
Total puts 678.1K 1.16M -41.7%
Total calls 569.6K 1.19M -52.3%
Total put/call ratio 1.2 1.0 +22.2%
Largest owners Shares Value Change
TROW T. Rowe Price 6.17M $693.57M +1.0%
Vanguard 3.43M $386.26M +0.3%
BLK Blackrock 3.23M $362.82M -2.3%
Brown Capital Management 2.34M $263.69M -11.3%
Alger Associates 2.22M $0 0.0%
Senvest Management 2.01M $226.54M +58.1%
Larry N Feinberg 1.81M $325.12M 0.0%
Fred Alger Management 1.71M $192.2M -23.1%
ArrowMark Colorado 1.5M $168.15M +67.8%
STT State Street 1.11M $124.46M +7.0%
Largest transactions Shares Bought/sold Change
Senvest Management 2.01M +740.32K +58.1%
ArrowMark Colorado 1.5M +603.98K +67.8%
Fred Alger Management 1.71M -514.3K -23.1%
Barrow Hanley Mewhinney & Strauss 0 -493.96K EXIT
Aqr Capital Management 606.65K +486.77K +406.0%
LGT Capital Partners 220.95K -445.11K -66.8%
Wellington Management 956.65K -433.46K -31.2%
Norges Bank 0 -421.54K EXIT
Armistice Capital 0 -328K EXIT
Burgundy Asset Management 323.49K +323.49K NEW

Financial report summary

?
Risks
  • The COVID-19 global pandemic could adversely affect our business operations, strategy, financial performance and results of operations, the extent of which is uncertain and difficult to predict.
  • The industry and market segment in which we operate are highly competitive, and intense competition with other providers of diagnostic products or services may reduce our sales and margins.
  • Our operating results are heavily dependent on sales of our COVID-19 and influenza diagnostic tests and if sales or revenues of our COVID-19 or influenza tests decline for any reason, our operating results would be materially and adversely affected.
  • We rely on a limited number of key distributors that account for a significant portion of our total revenue. The loss of any key distributor or an unsuccessful effort by us to directly distribute our products could lead to reduced sales.
  • Our results of operations and financial condition may be adversely affected by the financial soundness of our customers and suppliers.
  • We may not achieve market acceptance of our products among physicians, healthcare providers or other customers, and this would have a negative effect on future sales.
  • Our total revenue could be affected by third-party reimbursement policies and potential cost constraints.
  • Unexpected increases in, or inability to meet, demand for our products and services could require us to spend considerable resources to meet the demand or harm our reputation and customer relationships if we are unable to meet demand.
  • Interruptions in the supply of raw materials, components, equipment and other products and services could adversely affect our operations and financial results.
  • Failures in our IT and storage systems, including as a result of cyber-security breaches, could significantly disrupt our business or force us to expend excessive costs.
  • Interruptions to our third-party IT service providers and/or the inability of our digital solutions to interoperate with certain operating systems could impair the delivery of our cloud-based solutions and negatively impact our business.
  • We face risks relating to our international sales, including inherent economic, political and regulatory risks, that could impact our financial performance, cause interruptions in our current business operations and impede our growth strategy.
  • Continuing worldwide political and social uncertainty, including tariffs, trade wars or social tensions, may adversely affect our business and prospects, both domestically and internationally.
  • Natural disasters, public health crises, political crises and other catastrophic events or other events outside of our control may disrupt our facilities or the facilities of third parties on which we depend and adversely affect our results of operations.
  • Risks Related to Our Pending Business Combination
  • Completion of the Combinations is subject to certain conditions, some of which are outside of the parties’ control, and if these conditions are not satisfied or waived, the Combinations will not be completed.
  • Failure to complete the Combinations could negatively impact our stock price and future business and financial results.
  • The BCA contains provisions that restrict our ability to pursue alternatives to the Combinations and, in specified circumstances, would require us to pay Ortho a termination fee.
  • We will incur significant transaction and merger-related costs in connection with the Combinations.
  • We may have difficulty attracting, motivating and retaining executives and other key employees due to uncertainty associated with the Combinations.
  • Our business relationships may be subject to disruption due to uncertainty associated with the Combinations.
  • Completion of the Combinations may trigger change-in-control or other provisions in certain agreements that we are party to.
  • Intellectual Property Risks
  • To remain competitive, we must continue to develop and obtain proprietary technology rights; otherwise, we may lose market share or need to reduce prices as a result of competitors selling lower priced or technologically superior products or services that compete with our products.
  • Intellectual property risks and third-party claims of infringement, misappropriation of proprietary rights or other claims against us could adversely affect our ability to market our products, require us to redesign our products or attempt to seek licenses from third parties, and materially adversely affect our operating results. In addition, the defense of such claims could result in significant costs and divert the attention of our management and other key employees.
  • Our COVID-19 products were approved by the FDA through an EUA and the loss of such authorization could have a material adverse impact on our business, results of operations, financial position and cash flows.
  • Our business and products are highly regulated by various governmental agencies. Our results of operations would be negatively affected by failures or delays in the receipt of regulatory approvals, clearances or authorizations, the loss of previously received approvals or other changes to existing laws and regulations that adversely impact our ability to manufacture and market our products.
  • Our contracts with government entities involve future funding, compliance, and possible sanctions risks.
  • If one or more of our products is claimed to be defective, we could be subject to claims of liability and harm to our reputation that could adversely affect our business.
  • We use hazardous materials in our business that may result in substantial claims against us relating to handling, storage or disposal.
  • Complying with various US federal, state and foreign privacy and data security laws and privacy requirements from our customers could cause us to incur substantial costs or require us to change our business practices in a manner adverse to our business.
  • Changes in tax law relating to multinational corporations could adversely affect our tax position.
  • Risks Related to Our Acquisitions
  • If we are not able to manage our growth strategy or if we experience difficulties identifying or integrating companies or technologies we may acquire, our operating results may be adversely affected.
  • Transitioning the BNP Business to Beckman presents certain risks to our business and operations.
  • We may need to raise additional funds to finance our future capital or operating needs, which could have adverse consequences on our operations and the interests of our stockholders.
  • Our debt, deferred and contingent payment obligations could materially adversely affect our financial condition and results of operations.
  • Our business could be negatively affected by the loss of or the inability to hire key personnel.
  • We are subject to, and may in the future become subject to, claims and litigation that could result in significant expenses and could ultimately result in an unfavorable outcome for us.
  • We are exposed to business risk which, if not covered by insurance, could have an adverse effect on our results of operations.
  • Changes in our tax rates or exposure to additional income tax liabilities or assessments could affect our profitability.
  • Some provisions of our charter documents and Delaware law may make takeover attempts difficult, which could depress the price of our common stock and inhibit our stockholders’ ability to receive a premium price for their shares.
  • Expectations of our performance related to ESG matters may impose additional costs on us and expose us to new risks.
Management Discussion
  • Our fiscal year is the 52 or 53 weeks ending the Sunday closest to December 31. Fiscal year 2021 was 52 weeks and fiscal year 2020 was 53 weeks.

Content analysis

?
Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability
H.S. sophomore Avg
New words: BCA, billion, Canadian, codified, compensatory, concentrated, consummation, Coronado, forma, fully, geopolitical, guidance, Holdco, human, immaterial, Incentive, Laguna, Letter, list, merger, mission, Nasdaq, Natriuretic, nominee, Orca, Ortho, paper, pay, plc, preliminary, pro, proposed, Retention, Retirement, scheme, small, surviving, Topco, Topic, UK, undertaken
Removed: absorb, antitrust, arising, assumed, back, beneficiary, billed, collected, computer, contractually, conversion, convertible, County, coupon, court, created, decide, decline, denominator, designed, distancing, distribution, entity, exceeded, exclusivity, expanded, facilitating, Family, favorable, finance, granting, half, inception, incur, infrastructure, Institute, instrument, issue, key, lawsuit, leaseback, licensing, limited, mask, matured, maturity, McKellar, meeting, milestone, narrow, Naturietic, NIH, obligation, offsetting, partner, partnership, power, preventative, proceed, productivity, protect, referred, reimbursed, relating, roll, safeguard, sale, Senior, show, social, sort, structured, successfully, Superior, trade, travel, trial, unbilled, unconsolidated, unemployment, unenforceable, variable, VIE, wearing